Steatotic Liver Disease Classification Is Dynamic, Affecting Clinical Trial Eligibility and Subclass-Specific Treatments
SLD and the subclassification hereof is highly dynamic, especially driven by changes in alcohol use and hepatic steatosis. This affects eligibility for clinical trials and clinical management of patients with SLD.
Authors
- Camilla Dalby Hansen (ORCID: https://orcid.org/0000-0002-5704-2485)
- Katrine Holtz Thorhauge (ORCID: https://orcid.org/0000-0003-0411-0373)
- Peter Andersen (ORCID: https://orcid.org/0009-0001-4278-3731)
- K. Bech (ORCID: https://orcid.org/0000-0002-3760-0689)
- Katrine Prier Lindvig (ORCID: https://orcid.org/0000-0001-7891-7706)
- Mads Israelsen (ORCID: https://orcid.org/0000-0001-9443-5846)
- Ida Falk Villesen (ORCID: https://orcid.org/0000-0001-7921-9707)
- Stine Johansen (ORCID: https://orcid.org/0000-0002-5031-2294)
- Aleksander Krag (ORCID: https://orcid.org/0000-0002-9598-4932)
- Johanne Kragh Hansen (ORCID: https://orcid.org/0000-0003-2898-5369)
- Nikolaj Torp (ORCID: https://orcid.org/0000-0002-4378-6256)
- Maja Thiele (ORCID: https://orcid.org/0000-0003-1854-1924)
- Helle Lindholm Schnefeld (ORCID: https://orcid.org/0009-0009-6566-9681)
- Ida Ziegler Spedtsberg
- Torben Hansen (ORCID: https://orcid.org/0000-0001-8748-3831)
- Emil Deleuran Hansen
- Ellen Lyngbeck Jensen
Institutions
- University of Copenhagen (DK)
- University of Southern Denmark (DK)
- Novo Nordisk Foundation (DK)
- Odense University Hospital (DK)
Publication Details
- Journal
- Clinical Gastroenterology and Hepatology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1016/j.cgh.2025.02.007
- Citations
- 19
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 25.73
Funders
- AstraZeneca
- Innovationsfonden
- National Research Foundation
- Danmarks Grundforskningsfond
- Novo Nordisk
- Novo Nordisk Fonden
- Tillotts Pharma
- Norgine
- H2020 European Institute of Innovation and Technology